Table 2. The prognostic significance of SERPINB5 mRNA in gastric cancer by Kaplan-Meier plotter.

Clinicopathological features	Overall survival		Progression-free survival
	Hazard ratio	p	Hazard ratio	P
Sex
Female	0.53 (0.34–0.83)	0.004	0.5 (0.31–0.81)	0.0042
Male	0.63 (0.51–0.77)	1.4e-05	0.62 (0.49–0.78)	6.7e-05
T
2	0.52 (0.34–0.79)	0.002	0.51 (0.33–0.78)	0.0019
3	0.62 (0.41–0.95)	0.026	0.74 (0.53–1.04)	0.086
4	0.55 (0.21–1.46)	0.23	0.64 (0.29–1.4)	0.26
N
0	0.41 (0.17–0.95)	0.032	0.4 (0.17–1.02)	0.048
1–3	0.58 (0.44–0.77)	9.7e-05	0.59 (0.45–0.77)	7.6e-05
1	0.46 (0.29–0.72)	0.00047	0.47 (0.31–0.72)	0.00038
2	0.68 (0.43–1.09)	0.11	0.69 (0.44–1.08)	0.1
3	0.62 (0.36–1.06)	0.079	0.67 (0.39–1.16)	0.15
M
0	0.59 (0.44–0.78)	0.00027	0.6 (0.45–0.79)	0.00025
1	1.79 (0.95–3.35)	0.067	1.71 (0.95–3.1)	0.072
TNM staging
I	0.25 (0.07–0.88)	0.02	0.31 (0.09–1.13)	0.062
II	0.28 (0.13–0.58)	3e-04	0.33 (0.16–0.68)	0.0014
III	0.59 (0.44–0.8)	0.00057	0.59 (0.38–0.93)	0.021
IV	0.64 (0.42–0.99)	0.042	0.8 (0.52–1.23)	0.31
Perforation
-	0.75 (0.47–1.18)	0.21	0.73 (0.47–1.13)	0.15
Differentiation
Well-differentiated	0.46 (0.18–1.14)	0.086
Moderately-differentiated	1.39 (0.73–2.66)	0.32	1.4 (0.75–2.61)	0.29
Poorly-differentiated	0.72 (0.45–1.14)	0.16	0.72 (0.43–1.21)	0.22
Lauren’s classification
Intestinal-type	0.55 (0.4–0.75)	0.00013	0.78 (0.55–1.11)	0.17
Diffuse-type	0.53 (0.37–0.77)	0.00054	0.45 (0.3–0.68)	9e-05
Mixed-type	0.38 (0.13–1.07)	0.058	0.2 (0.06–0.66)	0.0039
Her2 positivity
−	0.63 (0.49–0.81)	0.00039	0.6 (0.46–0.82)	0.00081
+	0.62 (0.48–0.8)	3e-04	0.54 (0.39–0.75)	0.00016
Treatment
Surgery alone	0.65 (0.48–0.88)	0.0044	0.62 (0.46–0.84)	0.0015
5-FU-based adjuvant	1.63 (1.11–2.4)	0.013	1.66 (1.13–2.45)	0.0091
Other adjuvant	0.46 (0.19–1.12)	0.079	0.5 (0.23–1.1)	0.079